枸橼酸倍维巴肽注射液 | China Drugs ListBevifibatide Citrate Injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 百奥泰生物制药股份有限公司Bio-Thera Solutions, Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 心血管Cardiovascular
- 公开来源记录的适应症
- 用于接受经皮冠状动脉介入术（包括冠状动脉内支架置入）的急性冠脉综合征患者，以降低急性闭塞、支架内血栓、无复流和慢血流的风险。For patients with acute coronary syndrome undergoing percutaneous coronary intervention, including coronary stent implantation, to reduce the risks of acute occlusion, in-stent thrombosis, no-reflow and slow flow.
- 适应症来源与口径
- 批准或修订日期为空或为占位值；尚未确认准确修订日期。An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.